Valuation: Rani Therapeutics Holdings, Inc.

Market Cap 63.11M 56.61M 51.73M 47.23M 88.98M 5.93B 91.78M 624M 249M 3.17B 237M 232M 9.99B P/E 2026 *
-3.15x
P/E 2027 * -2.88x
Enterprise Value 63.11M 56.61M 51.73M 47.23M 88.98M 5.93B 91.78M 624M 249M 3.17B 237M 232M 9.99B EV / Sales 2026 *
10.1x
EV / Sales 2027 * 9.52x
Free-Float
4.26%
Yield 2026 *
-
Yield 2027 * -
1 day+5.93%
1 week-7.32%
Current month-7.32%
1 month-32.67%
3 months-30.96%
6 months-41.27%
Current year-59.50%
1 week 0.51
Extreme 0.51
0.6
1 month 0.51
Extreme 0.51
0.82
Current year 0.51
Extreme 0.51
1.54
1 year 0.51
Extreme 0.51
2.16
3 years 0.39
Extreme 0.387
8.75
5 years 0.39
Extreme 0.387
36.27
10 years 0.39
Extreme 0.387
36.27
Manager TitleAgeSince
Chief Executive Officer 45 01/06/2021
Director of Finance/CFO 46 29/06/2026
Chief Tech/Sci/R&D Officer 42 01/01/2022
Director TitleAgeSince
Chairman 69 01/06/2021
Director/Board Member 80 01/09/2018
Director/Board Member 70 06/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/9/26 Tax

Chief Executive Officer

-7,928 0.0080%
27/9/26 Tax

Chief Technology Officer

-309 0.0003%
3/8/26 Free

Director

247,200 0.2479%
Change 5-day change 1-year change 3-year change Capi.($)
+5.93%-7.32%-72.93%-72.38% 63.11M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +1.61%+1.65%+36.97%+160.15% 40.68B
Weighted average by Cap. +0.65%+3.07%+49.88%+165.84%

Financials

2026 *2027 *
Net sales 6.26M 5.61M 5.13M 4.68M 8.82M 588M 9.1M 61.82M 24.65M 314M 23.49M 22.98M 991M 6.63M 5.95M 5.44M 4.96M 9.35M 623M 9.64M 65.53M 26.13M 333M 24.9M 24.36M 1.05B
Net income -31.46M -28.22M -25.79M -23.54M -44.35M -2.96B -45.75M -311M -124M -1.58B -118M -116M -4.98B -36.73M -32.94M -30.1M -27.48M -51.78M -3.45B -53.41M -363M -145M -1.84B -138M -135M -5.82B
Net Debt - -
Projected Income Statement - Annual - Rani Therapeutics Holdings, Inc.
Logo Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Employees
70
Date Price Change Volume
06/11/26 USD 0.5468 +5.93% 462,617
05/11/26 USD 0.5162 -9.88% 697,746
04/11/26 USD 0.5728 +3.06% 286,187
03/11/26 USD 0.5558 +0.72% 651,953
02/11/26 USD 0.5518 -6.47% 415,910
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rani Therapeutics Holdings, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.5468USD
Average target price
7.200USD
Spread / Average Target
+1,216.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rani Therapeutics Holdings, Inc.
  1. Stock Market
  2. Stocks
  3. RANI Stock